Enoxaparin sodium won three major injections of Anda Jianyou Co., Ltd. and stirred nearly 9 billion markets

On the evening of December 1, Jianyou announced that the company had recently received the approval notice of USP anda for enoxaparin sodium injection issued by FDA According to the data of minenet, in 2018, the sales volume of terminal low molecular weight heparin of public medical institutions in China was 8.732 billion yuan, and three injections of Jianyou Co., Ltd were sold on the market Enoxaparin sodium injection belongs to low molecular weight heparin sodium, which can be used to prevent venous thromboembolism disease (prevent the formation of venous thrombosis) On May 30, 2014, Jianyou Co., Ltd first submitted the registration application for seven specifications of the product to FDA, which was accepted on December 12 of the same year On November 29, 2019, Jianyou Co., Ltd received the final approval from FDA and was qualified to sell the product in the U.S market Up to now, Jianyou has invested about 123 million yuan in the R & D project of the product According to the data of minenet, in recent years, the sales volume of LMWH in the terminals of public medical institutions in China has been increasing year by year, with an average annual growth rate of double digits In 2018, the sales volume reached 8.732 billion yuan, an increase of 26.27% year on year At present, the low molecular weight heparin sold on the domestic market includes low molecular weight heparin calcium injection, enoxaparin sodium injection, nadroparin calcium injection, heparin sodium injection, etc Jianyou Co., Ltd has three low molecular weight heparin injections on the market, namely enoxaparin sodium injection, Nadroparine calcium injection and daparin sodium injection The total sales of the three products in the terminals of public medical institutions in China in 2018 is 490 million yuan.